ArticleCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2026
Cost-effectiveness of implementing the National Health Service England Diabetes Prevention Programme in Canada: a modelling study.
Article in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The National Health Service (NHS) England's Diabetes Prevention Programme (DPP) is a cost-effective, publicly funded program of structured dietary and physical activity counselling that has been shown to reduce the incidence of progression from prediabetes to type 2 diabetes. We sought to examine the cost-effectiveness of implementing an NHS England-style DPP in Quebec and Ontario.
methodsWe compared usual care for people with prediabetes with a DPP using a cohort-state transition Markov model of 4 mutually exclusive health states (normal glucose tolerance, prediabetes, type 2 diabetes, and death) over a 35-year time horizon, run separately for Quebec and Ontario. We sourced transition probabilities, costs, and utilities from Canadian sources, the NHS England DPP, and published literature. We modelled the reduction in progression from prediabetes to type 2 diabetes using effectiveness data from the first 3 years of follow-up from the NHS England DPP. We adopted a health care system perspective and used a 1.5% annual discount rate. We presented costs in 2025 Canadian dollars and effectiveness in quality-adjusted life-years (QALYs). We generated base-case results using probabilistic analysis with 10 000 simulations.
resultsThe mean total costs of the DPP strategy were $101 833 per participant in Quebec and $101 835 in Ontario, compared with $102 077 for usual care, yielding incremental cost savings of $244 per participant in Quebec and $242 in Ontario. The 95% uncertainty range (UR) for incremental costs was -$1017 to $405 in Quebec and -$1016 to $408 in Ontario. The DPP generated a mean gain of 0.060 QALYs per participant (95% UR 0.024 to 0.094). It was less costly and more effective than usual care in 74.8% of simulations in Quebec and 74.7% in Ontario. Sensitivity analyses confirmed robustness to parameter uncertainty.
interpretationAn NHS England-style DPP would be cost-effective in Ontario and Quebec. Our findings support the potential value of investing in DPPs in Canada and highlight an opportunity to reduce the burden of type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.